Philip T. Sager, M.D, FACC, FAHA, FHRS is an Adjunct Professor at the Stanford University, the previous chair of the FDA Cardio-Renal Advisory Committee and an Executive Comm. member of the Cardiac Safety Research Consortium. He is a member of the ICH E14 QT Group and is on the Steering Comm, Comprehensive In Vitro Proarrhythmia Assay effort. He holds an M.D. from Yale University and B.S. degrees in biology and chemistry from the MIT and has published more than 200 manuscripts and abstracts.

Norman Stockbridge, MD, PhD has been in FDA/CDER's Division of Cardiovascular and Renal Products since 1991 and has been its Director since 2004.

Gary Gintant is a Research Fellow in the Dept. of Integrative Pharmacology, Global Pharmaceutical R&D, AbbVie. He is also a member of the CiPA Steering Committee and Co-Chair of the HESI Stem Celll-Cardiomyocyte Working Group.